Oncotelic Therapeutics, Inc. (OTLC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 500K 1M 1.5M Q1 '12: 114K Q2 '12: 0 Q3 '12: 0 Q4 '12: 42K Q3 '13: 95K Q4 '13: 0 Q1 '20: 340.9K Q2 '20: 1.4M Q3 '20: 0 Q4 '20: 0 Q3 '23: 70K Q4 '23: 0 Q2 '26: 250K Q1 '12 Q3 '12 Q3 '13 Q1 '20 Q3 '20 Q3 '23 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '21: -1.8M Q4 '21: -1.5M Q1 '22: -4.3M Q2 '22: -256.3K Q3 '22: -595.4K Q4 '22: -4.5M Q1 '23: -264.1K Q2 '23: -6.3M Q3 '23: 14.5K Q4 '23: -113.5K Q1 '24: -167.2K Q2 '24: -96.6K Q3 '24: -3.3M Q4 '24: -31.5K Q1 '25: -101.1K Q2 '25: -66K Q3 '25: -491K Q4 '25: -2.5M Q1 '26: -1.9M Q2 '26: -843.6K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-90M 0 90M 180M 270M Q3 '21: -1.6M Q4 '21: -1.8M Q1 '22: -4.8M Q2 '22: 16M Q3 '22: -777.9K Q4 '22: -5.3M Q1 '23: -525.4K Q2 '23: -6.8M Q3 '23: 115.3K Q4 '23: -736K Q1 '24: -408.7K Q2 '24: -209.8K Q3 '24: -3.3M Q4 '24: -600.9K Q1 '25: -298.7K Q2 '25: 277.9K Q3 '25: -1M Q4 '25: 250.3M Q1 '26: -2.2M Q2 '26: 388.1K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-1.2M -800K -400K 0 400K 800K 1.2M Q3 '21: -900.7K Q4 '21: -1.1M Q1 '22: -962.7K Q2 '22: -203.1K Q3 '22: -206.1K Q4 '22: -80.7K Q1 '23: -251K Q2 '23: -448.6K Q3 '23: -248.8K Q4 '23: -372.6K Q1 '24: -231.4K Q2 '24: -261.8K Q3 '24: -143.2K Q4 '24: -103.9K Q1 '25: -167K Q2 '25: -126.2K Q3 '25: -307K Q4 '25: -783K Q1 '26: -342.2K Q2 '26: -92.2K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-3M -2M -1M 0 1M 2M 3M Q3 '15: -2.8M Q3 '15

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 200M 400M 600M Q2 '19: 65.4M Q2 '20: 94.7M Q3 '20: 89M Q1 '21: 94.2M Q2 '21: 369.5M Q3 '21: 370.4M Q1 '22: 377.4M Q2 '22: 418.8M Q3 '22: 386.8M Q1 '23: 392.4M Q2 '23: 394.4M Q3 '23: 397.8M Q1 '24: 399.4M Q2 '24: 401.6M Q3 '24: 407.3M Q1 '25: 407.4M Q2 '25: 452.8M Q3 '25: 426.4M Q1 '26: 443.8M Q2 '26: 467.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.25 0.00 0.25 0.50 0.75 Q3 '21: -0.08 Q4 '21: -0.04 Q1 '22: -0.02 Q2 '22: 0.03 Q3 '22: 0.03 Q4 '22: 0.01 Q1 '23: 0.02 Q2 '23: -0.04 Q3 '23: -0.04 Q4 '23: -0.02 Q1 '24: -0.02 Q2 '24: 0.00 Q3 '24: -0.01 Q4 '24: -0.01 Q1 '25: -0.01 Q2 '25: -0.01 Q3 '25: 0.00 Q4 '25: 0.59 Q1 '26: 0.59 Q2 '26: 0.59 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.